ATLAS News · Pharmaceuticals

Propranolol and metoprolol blood pressure drugs recalled in the US

Published November 17, 2026 · Updated November 17, 2026 · 3 sources

Breckenridge recalled one lot of propranolol capsules over possible metal contamination, and Advagen recalled metoprolol tablets over foreign tablets or capsules.

What happened

Breckenridge Pharmaceutical is voluntarily recalling one lot of propranolol hydrochloride extended-release capsules over potential metal contamination [2]. Separately, Advagen Pharma Limited is recalling bottles of metoprolol tartrate tablets because of the presence of foreign tablets or capsules, according to a report citing an FDA notice [3].

Breckenridge said it is recalling to the consumer level one lot of Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg, manufactured by Adare Pharma Solutions, due to potential metal contamination. The company said the affected lot shared intermediate material suspected to be the source of metal contamination found in a separate lot that was not released to market [2].

Breckenridge said use of the affected product could potentially cause lacerations of soft tissues in the oral cavity, esophagus, stomach, or intestine. It said it is not aware of any adverse events assessed to be related to the recall [2].

The company said the lot was distributed nationwide to wholesalers and pharmacies between October 26, 2026 and November 04, 2026. Consumers should immediately stop taking product from the lot, contact their physician or healthcare provider, and return any unused portion to the pharmacy where it was obtained [2].

A report says Advagen Pharma Limited is recalling 3,684 bottles of metoprolol tartrate tablets, USP, in 50-milligram doses, each holding 1,000 tablets. The report says the notice gave the reason as the presence of foreign tablets or capsules, and did not provide more details. The batch number is 2611C065A1, with an expiration date of May 2028 [3]. A headline also describes a nationwide blood pressure medication recall over possible metal contamination [1].

Related companies and sectors

Sector relationship, not a demonstrated effect: ATLAS has no evidence that this story moves these companies' share prices. They appear for their activity in the sector and are shown with ATLAS data.

Generic drug maker in the cardiovascular segment, where the recalled blood pressure medications compete. · Healthcare

Latest available close
$20.70Close of November 16
Fair value (ATLAS)
$31.43Fair range: $20.81 to $50.86The price ($20.70) is 34.1% below that figure.
Chance of a rise in 1 month
51%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $19.65 and $21.88; 9 in 10, between $17.87 and $24.07.
See the full ATLAS analysis of Viatris →

Large generic pharmaceutical manufacturer operating in the same therapeutic market as the recalled drugs. · Healthcare

Latest available close
$43.01Close of November 16
Fair value (ATLAS)
$18.26Fair range: $14.47 to $24.19The price ($43.01) is 135.5% above that figure.
Chance of a rise in 1 month
51%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $40.77 and $45.52; 9 in 10, between $36.97 and $50.19.
See the full ATLAS analysis of Teva Pharmaceutical Industries →

Pharmaceutical distributor that handles product recalls and withdrawals for pharmacies and providers. · Healthcare

Latest available close
$284.21Close of November 16
Fair value (ATLAS)
$300.97Fair range: $163.26 to $554.85The price ($284.21) is 5.6% below that figure: close to its fair value.
Chance of a rise in 1 month
52%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $273.47 and $297.37; 9 in 10, between $253.89 and $320.30.
See the full ATLAS analysis of Cardinal Health →

Pharmacy and PBM operator that dispenses recalled prescriptions to consumers and manages recall notices. · Healthcare

Latest available close
$88.38Close of November 16
Fair value (ATLAS)
$205.56Fair range: $185.00 to $226.11The price ($88.38) is 57.0% below that figure.
Chance of a rise in 1 month
49%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $81.28 and $95.48; 9 in 10, between $70.47 and $110.12.
See the full ATLAS analysis of CVS Health →

ATLAS data for these companies

ATLAS model estimates place the fair value of Viatris at $31.43, with the November 16 close 34.14% below it, and Cardinal Health at $300.97, with the close 5.57% below. For CVS Health the estimate is $205.56, with the close 57.00% below it, while Teva's close is 135.48% above its estimate of $18.26. These are model estimates, not promises, and they are not tied to this story.

This is a sector relationship, not a demonstrated effect: there is no evidence that this story moves these companies' share prices. The figures come from closes and may change.

What you get with ATLAS

  • Fair value of each company, with its range, against today's price.
  • Chance of a rise in 1 month and the normal price range, from a calibrated model.
  • Earnings: next date, estimated EPS and surprise history.
  • Dividends and alerts by email when a company reports.
Create my ATLAS account →

Start in under a minute. Information, not advice.

Frequently asked questions

Does this news affect stocks in the sector?

There is no evidence of that. The companies listed have a sector relationship to the story, not a demonstrated effect.

What should consumers of the recalled propranolol do?

Breckenridge says consumers should immediately stop taking product from the affected lot, contact their physician or healthcare provider, and return unused product to the pharmacy [2].

What is the reason for the metoprolol recall?

A report citing an FDA notice gives the reason as the presence of foreign tablets or capsules, and says the notice gave no further details [3].

Sources

  1. Blood pressure medication recalled nationwide over possible metal contamination · NBC 5 Chicago
  2. Breckenridge Pharmaceutical, Inc. Issues Voluntary Nationwide Consumer-Level Recall of One Lot of Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg, Due to Potential Metal Contamination · PR Newswire · November 16, 2026
  3. Blood pressure medication recalled over ‘foreign tablets’ · Santa Clarita Valley Signal · November 16, 2026

Closing prices, fair value, probabilities, earnings and dividends: ATLAS own data as of November 17, 2026. How we calculate fair value.

Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer

ATLAS Signals

ATLAS Signals, every week

The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.

By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy